Invitrogen, PCT to Co-Develop, Market Invitrogen’s Media and Cell-Separation Technologies | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen and Progenitor Cell Therapy today said they will co-develop and -market Invitrogen’s media and cell separation technologies, PCT said today.
The agreement will include marketing, co-referrals, joint proposals, and technical consulting around Invitrogen’s Dynabeads and Dynabeads ClinExVivo, which are ex vivo T-cell and immune-functioning technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.